

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549

DIVISION OF CORPORATION FINANCE

September 17, 2020

Leen Kawas, Ph.D. Chief Executive Officer Athira Pharma, Inc. 4000 Mason Road, Suite 300 Seattle, WA 98195

Re: Athira Pharma, Inc.

**Registration Statement on Form S-1** 

Exhibit No. 10.9 Filed August 26, 2020 File No. 333-248428

Dear Dr. Kawas:

We have concluded our assessment of your redacted exhibit for compliance with applicable form requirements and will process your supplemental response and related materials in accordance with your request.

Sincerely,

Division of Corporation Finance